Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Study Overview
=================
Brief Summary
-----------------
To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression

Official Title
-----------------
Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy

Conditions
-----------------
Living-Donor Kidney Transplant

Intervention / Treatment
-----------------
* Drug: Thymoglobulin
* Drug: Campath-1H
* Drug: Daclizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been fully informed and has signed a dated IRB approval informed consent form and is willing to follow study procedures for the extent of the study (36 months). Parent or legal guardian must provide written consent for patients <18 years of age. Age 16-65 years Weight > 40 kg Primary renal allograft: living related (non HLA identical) and unrelated donor Negative standard cross-match for T-cells. All donor-recipient pairs matched for a minimum of 1 HLA DR antigen. (Standard at our center) Women of childbearing potential will be required to have a negative qualitative serum pregnancy test and agree to use an adequate method of contraception for 3 months following discontinuation of Thymoglobulin or Campath-1H Males and females are to be studied equivalently as they become available for transplantation using these criteria. Exclusion Criteria: Patient has previously received or is receiving an organ transplant other than a kidney. Patient is receiving an ABO incompatible donor kidney. Recipient or donor is seropositive for human immunodeficiency virus (HIV), Hepatitis C viruses, or Hepatitis B virus antigenemia. Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully or carcinoma in situ of the cervix that has been treated successfully. Patients with significant liver disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range of this center. Patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or an active peptic ulcer or any other unstable medical condition that could interfere with study objectives. Patient is currently participating in another clinical trial of an investigational drug in the 30 days prior to transplant. Patient will be receiving any immunosuppressive agent other that those prescribed in the study. Patient is unable to take medications orally or via nasogastric tube by the morning of the second day following completion of the transplant procedure (i.e. skin closure). Patient is receiving or may require warfarin, fluvastatin or herbal supplements during the study. Concurrent use of astemizole, pimozide, cisapride, terfenadine, or ketoconazole. Patient has a known hypersensitivity to Tacrolimus, Campath-1H, Thymoglobulin, Daclizumab (Zenapax®), Sirolimus, MMF or corticosteroids. Patient is pregnant or lactating. Patients with a screening/baseline (or within 96 hours of transplant) total white blood cell count <4000/mm3; platelet count <100,000/mm3; fasting triglycerides >400 mg/dl (>4.6 mmol/L); fasting total cholesterol >300 mg/dl (>7.8 mmol/L); fasting HDL-cholesterol <30 mg/dl; fasting LDL-cholesterol >200mg/dl. Patient is unlikely to comply with the visits scheduled in the protocol. Patient has any form of substance abuse, psychiatric disorder or a condition that, in opinion of the investigator, may invalidate communication with the investigator. If tacrolimus cannot be instituted for longer than 5 days postoperatively.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Thymoglobulin Induction | Drug: Thymoglobulin<br>* Induction<br>|
| Experimental: B<br>Campath-1H Induction | Drug: Campath-1H<br>* Induction<br>* Other names: Alemtuzumab;|
| Experimental: C<br>Daclizumab Induction | Drug: Daclizumab<br>* Induction<br>* Other names: Zenapax;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and severity of biopsy-proven acute rejection at 1 year. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient and graft survival |  | 1 and 3 years | 
| Incidence of biopsy-proven chronic allograft nephropathy. |  | 1 and 3 years | 
| Levels of lymphoid cell subsets. |  | 1 and 3 years | 
| Incidence of adverse reactions, for example: Infections, Malignancies, Thromboembolic events. |  | 1 and 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Randomized, study, effectiveness/toxicity, induction therapy, recipients